Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
39
PROCF Quote, Financials, Valuation and Earnings
Last price:
$0.05
Seasonality move
:
-12.22%
Day range:
$0.05 - $0.98
52-week range:
$0.01 - $2.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.01x
P/B ratio:
549.06x
Volume:
7.2K
Avg. volume:
447
1-year change:
-97.87%
Market cap:
$115.2M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sofgen Pharma SA has 9900% upside to fair value with a price target of -- per share.
PROCF vs. S&P 500
-
Over the past 5 trading days, Sofgen Pharma SA has overperformed the S&P 500 by 99.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sofgen Pharma SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sofgen Pharma SA has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Sofgen Pharma SA reported revenues of --.
Earnings Growth
-
Sofgen Pharma SA earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Sofgen Pharma SA reported earnings per share of --.
Enterprise value:
396.2M
EV / Invested capital:
--
Price / LTM sales:
0.01x
EV / EBIT:
8.88x
EV / Revenue:
0.94x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
9.90x
Price / Operating cash flow:
0.13x
Enterprise value / EBITDA:
6.31x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $409.7M | $409.9M | $423.7M | $101.5M | $111.1M | |
| Gross Profit | $235.7M | $192.4M | $238M | $52.3M | $62.3M | |
| Operating Income | $70.5M | -- | $44.6M | $2.2M | $13.1M | |
| EBITDA | $90M | -- | $62.8M | $6.7M | $18.3M | |
| Diluted EPS | -$2.27 | $0.25 | $0.40 | $0.09 | -$0.01 | |
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.6M | $721.2K | $298.1M | $279.3M | $275.6M | |
| Total Assets | $202.1M | $202.1M | $462.1M | $442.5M | $472.5M | |
| Current Liabilities | $60.8K | $32K | $188M | $386.3M | $401.7M | |
| Total Liabilities | $60.8K | -- | $500.5M | $479.7M | $473.2M | |
| Total Equity | $202.1M | $202M | -$38.3M | -$37.1M | -$736K | |
| Total Debt | -- | -- | $253.4M | $38.2M | $36.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $18M | -- | $72.8M | -$7.8M | $26.4M | |
| Cash From Investing | -$25.5M | -- | -$34.6M | -$11.8M | -$14.3M | |
| Cash From Financing | $89.9M | -- | -$63M | $28.8M | -$14.1M | |
| Free Cash Flow | -$8.4M | -- | $40M | -$18.8M | $14M | |
PROCF
Sector
Market Cap
$115.2M
$27.9M
Price % of 52-Week High
2.1%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.55%
1-Year Price Total Return
-97.87%
-17.49%
Beta (5-Year)
61.716
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.03
200-day SMA
Sell
Level
$0.94
Bollinger Bands (100)
Sell
Level
0.02 - 1.24
Chaikin Money Flow
Sell
Level
-7.2K
20-day SMA
Buy
Level
$0.03
Relative Strength Index (RSI14)
Sell
Level
40.54
ADX Line
Buy
Level
7.14
Williams %R
Buy
Level
-97.3951
50-day SMA
Sell
Level
$0.31
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
7.2K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sofgen Pharma SA is an international healthcare and pharmaceutical company. The firm is engaged in the developing of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It operates through the following segments: NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. The NextGel segment is involved in the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in USA, Brazil, and Colombia. The Procaps Colombia segment is focused on the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Colombia. The CAN segment deals with the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Northern Central America: Salvador, Guatemala, Nicaragua, and Honduras. The CASAND segment offers pharmaceutical products in Southern Central America that include Panama and Costa Rica, and the North Andes District that include Ecuador, Peru, and Bolivia. The Diabetrics segment consists of the diabetes solutions and chronic disease management tool. The company was founded by Ruben Minski in 1977 and is headquartered in Luxembourg.
Stock Forecast FAQ
In the current month, PROCF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PROCF average analyst price target in the past 3 months is --.
-
Where Will Sofgen Pharma SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sofgen Pharma SA share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Sofgen Pharma SA?
Analysts are divided on their view about Sofgen Pharma SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sofgen Pharma SA is a Sell and believe this share price will drop from its current level to --.
-
What Is Sofgen Pharma SA's Price Target?
The price target for Sofgen Pharma SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PROCF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sofgen Pharma SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PROCF?
You can purchase shares of Sofgen Pharma SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sofgen Pharma SA shares.
-
What Is The Sofgen Pharma SA Share Price Today?
Sofgen Pharma SA was last trading at $0.05 per share. This represents the most recent stock quote for Sofgen Pharma SA. Yesterday, Sofgen Pharma SA closed at $0.05 per share.
-
How To Buy Sofgen Pharma SA Stock Online?
In order to purchase Sofgen Pharma SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PROCF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PROCF
Sector
P/E ratio
--
23.75x
PEG ratio
0.00x
-0.01x
P/B ratio
549.06x
1.81x
Price / LTM sales
0.01x
1.59x
Growth Metrics
PROCF
Sector
Revenue growth
--
4.6%
Earnings growth
--
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.21
Profitability
PROCF
Sector
Profitability FY 2025
--
$3.6M
Return on invested capital
--
-31.84%
Return on assets
--
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Jun
24
Next Earnings Date
Dec
31
Estimated Next Earnings Date
Apr
1
Balance Sheet
PROCF
Sector
Total cash
--
$26.3M
Short term investments
--
$25.7M
Total assets
--
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
